UNIVERSITY OF CINCINNATI

UC researchers use 3D bioprinting to create artificial blood vessels for testing custom-tailored drugs against glioblastoma, aiming to understand tumor regeneration and drug resistance, published in *Advanced Healthcare Materials*.

Donanemab, an Alzheimer’s drug by Eli Lilly, faces scrutiny over excess deaths, missing safety data, questionable efficacy, and financial conflicts among FDA advisory panel members. Despite these concerns, the FDA approved the drug in July 2023, raising questions about the approval process and the drug's true benefits and risks.

FDA-approved Alzheimer’s drug donanemab faces scrutiny over effectiveness, safety, and undisclosed financial conflicts among FDA advisers who recommended its approval.

New research suggests Alzheimer's may result from reduced amyloid-beta levels, not increased build-up, and boosting brain protein Aβ42 could slow cognitive decline.

Two stroke types exist; one drug treats Ischemic strokes, another is tested for brain bleeds. Neurologist Joseph Broderick leads a global study on Recombinant Factor 7A to stop brain bleeding. A mobile stroke unit expedites treatment, using 'exception from informed consent' for urgent cases.

Ohio's successful recruitment and education of risk management and insurance talent, driven by collaborative efforts between insurance companies, universities, and stakeholders, offers a model for other regions to emulate.

The FDA will respond to the New Drug Application for Bristol Myers Squibb and Karuna Therapeutic’s schizophrenia drug, KarXT, by September 26, 2024. KarXT, a muscarinic M1/M4 agonist, shows promise in reducing schizophrenia symptoms without metabolic, endocrine, or motor adverse effects, potentially positioning it as a first-line treatment alongside standard serotonin/dopamine antagonists.

A new DHODH inhibitor, HOSU-53, developed at The Ohio State University, will undergo a clinical trial for cancer treatment, targeting key cellular metabolic processes essential for cancer growth.

Alzheimer's drugs Leqembi and Kisunla may work by boosting levels of healthy amyloid beta (Aβ42) protein, countering Alzheimer's progression, according to a University of Cincinnati study.